On June 17, 2026, ACTAVIS LABS FL received FDA approval for the brand-name and generic versions of My Health Inc.'s ALDH2 inhibitor, impermexanate, signaling an imminent entry for a blockbuster compound that could challenge pricing power in the heavy ALDH2 inhibitor market and accelerate competitive dynamics within the sector.